PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
PTC Therapeutics, Inc.NASDAQ: PTCT
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $83.5M, compared with -$64.85M a year earlier. Trailing-twelve-month net income was -$38.38M.
Context
- Net income amounted to 39.4% of revenue in FY2025, down 5.6 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of $69.82M (-89.8%) for the fiscal year ending Dec 2026, a slowdown from the +287.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $83.5M+3072.4% QoQ
- Last fiscal yearDec 2025
- $682.64M+287.9% YoY
- LTMJun 2026
- -$38.38M-106.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +228.8% | -24.7% | -253.5 pp |
| 1 year | +287.9% | -89.8% | -377.7 pp |
| 3-year CAGR | — | -20.0% | — |
| 5-year CAGR | -6.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 682.64M USD
- Year-over-year change
- +287.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 682.64M | +287.9% |
| FY2024 | 2024-12-31 | (363.3M) | +42.0% |
| FY2023 | 2023-12-31 | (626.6M) | -12.1% |
| FY2022 | 2022-12-31 | (559.02M) | -6.7% |
| FY2021 | 2021-12-31 | (523.9M) | — |
Net Income vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 net income of $38.38M is the smallest of the 11 companies compared; the peer median is $355.59M.
- Its year-over-year change of -106.1% is the lowest of 11, against a peer median of +64.0%.
- Net income amounts to 3.8% of revenue for PTCT, versus a peer median of 56.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B | +146477.0% | +53.5% | — | |
| LTM Sep 2026 | $27.6B | +3808.4% | +35.1% | 2.7% | |
| LTM Jun 2026 | $695.45M | -11.4% | +14.4% | 97.5% | |
| LTM Mar 2026 | $608.92M | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $546.15M | +113.1% | +12.2% | 56.9% | |
| LTM Jun 2026 | $519.41M | +25.8% | +38.5% | — | |
| LTM Jun 2026 | $241.47M | +64.6% | — | 54.8% | |
| LTM Mar 2026 | $191.78M | +37.3% | +26.6% | — | |
| LTM Mar 2026 | $183.59M | +63.4% | +8.1% | 255.7% | |
| LTM Mar 2026 | $65.06M | +126.2% | +0.5% | 3.0% | |
| LTM Jun 2026 | $38.38M | -106.1% | — | 3.8% | |
| Peer median (excluding PTCT) | $355.59M | +64.0% | +14.4% | 56.9% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| Deferred Income Tax | 377K | (34.28M) | (46.93M) | (55.91M) | (3K) |
| Stock-Based Compensation | 103.51M | 110.33M | 131.21M | 74.62M | 74.55M |
| Change in Working Capital | (23.79M) | (85.34M) | (4M) | 102.54M | (47.88M) |
| Accounts Receivables | (44.99M) | (48.47M) | (1.54M) | 1.73M | (10.15M) |
| Inventory | 1.8M | (6.67M) | (8.18M) | 6.16M | (53.9M) |
| Accounts Payables | 23.41M | 27.54M | 0 | 0 | 0 |
| Other Working Capital | (4.01M) | (57.74M) | 5.72M | 94.65M | 16.17M |
| Other Non-Cash Items | 128.33M | 82.81M | 151.32M | 58.7M | (36.93M) |
| Operating Cash Flow | (251.33M) | (356.65M) | (158.42M) | (107.69M) | 711.2M |
| Capital Expenditures | (85.33M) | (152.46M) | (120.62M) | (74.25M) | (300.01M) |
| Acquisitions (Net) | 57.12M | 128.44M | 0 | 0 | 0 |
| Purchases of Investments | (543.27M) | (75.55M) | (212.48M) | (667.36M) | (1.42B) |
| Sales of Investments | 847.78M | 518.19M | 156.37M | 607.74M | 855.12M |
| Other Investing Activities | (57.12M) | (128.44M) | (92.18M) | 110.31M | (291.08M) |
| Investing Cash Flow | 219.18M | 290.18M | (176.74M) | 44.18M | (861.98M) |
| Debt Repayment | (2.22M) | 148.72M | (301.38M) | (1.49M) | (1.61M) |
| Common Stock Issued | 23.1M | 50M | 0 | 0 | 99.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (30.77M) | 947.78M | 257.36M | 233.66M |
| Financing Cash Flow | 20.88M | 167.95M | 646.4M | 255.87M | 331.09M |
| Effect of Forex Changes | (7.82M) | (2.77M) | 3.11M | (7.33M) | 22.71M |
| Net Change in Cash | (19.09M) | 98.71M | 314.36M | 185.03M | 203.02M |
| Free Cash Flow | (336.66M) | (509.11M) | (279.04M) | (181.94M) | 411.18M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.